Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122730 | 0.94 | CASP2 (0.50) | CASP2CNR1NAAAFAAHDNM1 | |
| SCHEMBL20323905 | 0.89 | TSHR (0.58) | CASP2CNR1NAAAFAAHCYP2C19 | |
| SCHEMBL25574266 | 0.89 | CASP2 (0.63) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL25415126 | 0.88 | NAAA (0.59) | CASP2CNR1NAAAFAAHCNR2 | |
| SCHEMBL5165598 | 0.88 | NAAA (0.59) | CASP2CNR1NAAAFAAHCNR2 | |
| SCHEMBL20325515 | 0.87 | FAAH (0.62) | CASP2NAAAFAAHCYP1A2CYP3A4 | |
| SCHEMBL11912076 | 0.87 | CASP2 (0.66) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL2124347 | 0.86 | CASP2 (0.44) | CASP2CNR1NAAAFAAHDNM1 | |
| SCHEMBL22343243 | 0.86 | CES2 (0.51) | CASP2CNR1NAAAFAAHDNM1 | |
| SCHEMBL21233609 | 0.86 | TSHR (0.49) | CASP2CNR1NAAAFAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020023851-A1 | BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE | YALE UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019195201-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018119448-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119357-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018053354-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |